09/763985

JCCT Rec'd PCT/PTD 2 8 FEB 2001

PATENT 0020-4817P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

ITOH et al.

Appl. No.:

New

Group:

Filed:

February 28, 2001

Examiner:

For:

NOVEL TUMOR ANTIGEN PROTEIN SART-3 AND

TUMOR ANTIGEN PEPTIDES THEREOF

INFORMATION DISCLOSURE STATEMENT (SUBMISSION CONCURRENT WITH THE FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents Washington, DC 20231

February 28, 2001

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- \Box Submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- \boxtimes This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO- $1\overline{4}\overline{4}9$ are not enclosed because they were cited in the International Search Report and copies should be forwarded from the International Search Authority. If copies are needed, please contact the undersigned.

Docket No. 0020-4817P

III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

a. DOCUMENTS IN THE ENGLISH LANGUAGE

The attached patents, publications, or other information in the English language do not require a statement of relevancy.

b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ME ENGLISH LANGUAGE SEARCH REPORT

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. OTHER

The following additional information is provided for the Examiner's consideration.

5001 Rec'd PCT/PTO 2 8 FEB 2001

Docket No. 0020-4817P

FEES

This Information Disclosure Statement being filed is concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § particularly, extension of time fees.

Respectfully submitted,
BIRCH, STEWART, KOLASCH & BIRCH, LLP By By
John W. Bailey, #32,881 P.O. Box 747 Falls Church, VA 22040-0747 (703) 205-8000
PTO-1449(s)
ents
gn Search Report
International Search Report

(Rev. 01/22/01)